Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma
Pediatric blood & cancer
Langerhans cell histiocytosis; clinical trial; non-Hodgkin lymphoma; pediatric oncology
Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children' Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.
El-Mallawany, Nader Kim; Alexander, Sarah; Fluchel, Mark; Hayashi, Robert J.; Lowe, Eric J.; Giulino-Roth, Lisa; Wistinghausen, Birte; Hermiston, Michelle; and Allen, Carl E., "Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma" (2023). GW Authored Works. Paper 3075.